January 06, 2025
Hi Erica, Please find our social listening snapshot below for 12/21 - 01/06, along with a dashboard snapshot PDF attached. Happy New Year!
LEO Pharma
Top LEO Pharma Company & Drug Discussions
- Company Mentions:
- LEO Pharma’s CEO reflects on a successful 2024 while thanking his colleagues and partners. (LinkedIn)
- tralokinumab (ADBRY):
- Dermatology Times publishes a 2024 year in review roundup, highlighting advances in atopic dermatitis including the ECZTRA and ECZTEND trials of tralokinumab/ADBRY, ADORING 1 and 2 trials of tapinarof/VTAMA, JADE trials of abrocitinib/CIBINQO, and ADvocate 1 and 2 trials of lebrikizumab/EBGLYSS. (Dermatology Times)
- A new paper is published in the Journal of Investigative Dermatology, “Tralokinumab Treatment of Atopic Dermatits Induces A Progressive Transcriptomic Response”. (NIH)
- After an individual on Reddit posts about DUPIXENT failing treatment, several others recommend switching to ADBRY or EBGLYSS. (Reddit)
- delgocitinib (Anzupgo):
- A systematic review and meta-analysis of janus kinase inhibitors in patients with vitiligo is published, mentioning delgocitinib. (ASCPT)
- Several stories about delgocitinib from throughout 2024 are mentioned in Dermatology Times’ Chronic Hand Eczema year in review article. (Dermatology Times)
Other top Atopic Dermatitis (AD) & Chronic Hand Eczema (CHE) Discussions
- Dermatology Advisor covers the FDA’s approval of VTAMA for AD. (Dermatology Advisor)
- Ikena Oncology has merged with immunology company Inmagene Biopharmaceuticals to focus on advancing IMG-007, a promising OX40-targeting monoclonal antibody for atopic dermatitis, under the new combined entity InmageneBio. (Fierce Biotech, The Manila Times, City Biz)
- Johnson & Johnson has secured global rights to Kaken Pharmaceutical’s STAT6 program, including the oral candidate KP-723 for atopic dermatitis, through a licensing deal that expands J&J’s autoimmune and allergic disease pipeline. (PM Live, Bio World, Web Wire, Med Watch)
- Castle Biosciences has reported preliminary data on a test designed to predict ‘super response’ to targeted therapies in moderate-to-severe atopic dermatitis, aiming to improve treatment precision and reduce trial-and-error approaches, with a planned launch by the end of next year. (Yahoo, MSN)
- Artificial intelligence is transforming atopic dermatitis management by improving diagnosis, enabling early and accurate detection, personalizing treatment plans, and facilitating continuous disease monitoring through innovations like AI-powered image recognition, wearable devices, and predictive analytics. (Yahoo, Indica News)
- A retrospective cohort study found that dupilumab (Dupixent) treatment for atopic dermatitis significantly reduced the risk of psychiatric and sleep disorders, particularly in Black or African American patients, compared to conventional treatments. (Pharmacy Times)
- The most-read dermatitis articles of 2024 highlighted a study linking dupilumab to an increased risk of cutaneous T-cell lymphoma, alongside research on the risks and benefits of atopic dermatitis treatments, associations with antihypertensive medications, and emerging insights into JAK inhibitors, metabolic syndrome, and dietary factors in atopic dermatitis management. (Healio)
- A study found that combining dupilumab with JAK inhibitors offers a promising and well-tolerated short-term treatment for refractory moderate-to-severe atopic dermatitis, with significant improvements in disease severity, quality of life, and pruritus reduction, though long-term safety and cost concerns remain. (Dermatology Times)
- Technoderma Medicines completed a successful Phase 2a trial of TDM-180935, a topical JAK1/Tyk2 inhibitor, demonstrating strong efficacy, minimal systemic absorption, and excellent tolerability for treating atopic dermatitis, paving the way for further development. (The Manilla Times)
- A clinical trial at RML Hospital demonstrated that Tofacitinib, a pan-JAK inhibitor, achieved a 90% improvement in symptoms for 80% of chronic hand eczema patients within four weeks, offering a promising treatment for this resistant and life-disruptive condition. (MSN)
- A study by the Institute of Science Tokyo reveals that tristetraprolin (TTP) regulates allergic inflammation by promoting the degradation of mRNAs encoding inflammatory cytokines in basophils, suggesting that targeting TTP could offer new therapeutic strategies for allergic diseases like asthma and atopic dermatitis. (News Medical Life Sciences)
- Chime Biologics and Mabgeek have achieved the Process Performance Qualification (PPQ) milestone for MG-K10, a humanized anti-IL-4Rα monoclonal antibody, advancing its Phase III clinical trials for treating Th2-mediated inflammatory diseases like atopic dermatitis and asthma, with the goal of accelerating commercialization in global markets. (The Malaysian Reserve)
Dr. Reddy’s Laboratories
- Company Mentions:
- Dr Reddy’s Laboratories has voluntarily recalled six lots of Sapropterin Dihydrochloride in the US due to concerns over discolouration that may affect the drug’s potency, though no adverse events have been reported. (MSN)
- Dr Reddy’s contract research arm, Aurigene, has opened a new 70,000 sq ft biologics facility in Hyderabad’s Genome Valley to provide process development, analytical services, and small-scale manufacturing of antibodies and recombinant proteins for preclinical and early-phase clinical needs. (MSN, Medical Dialogues)
- denosumab:
- GlycoNex has announced a licensing agreement for its denosumab biosimilar, SPD8, which has entered Phase 3 clinical trials, marking a key milestone in the company’s global expansion strategy to address osteoporosis and skeletal-related events in cancer patients. (Yahoo)
- COYA 302:
- ALS News Today highlights the trial of COYA 302 for ALS as a top 10 ALS story of 2024. (ALS News Today)
Paratek Pharmaceuticals
- omadacycline (NUZYRA):
- A case report of Mycobacterium abscessus-related peritoneal dialysis (PD)-associated peritonitis treated with clofazimine and omadacycline is published. (PPID Journal)
Argenx
Top Argenx Company & Drug Discussions
- efgartigimod (VYVGART):
- A post-hoc analysis of the ADAPT clinical trial and its extension confirms that efgartigimod (VYVGART) provides sustained improvement in strength and function for patients with generalized myasthenia gravis and acetylcholine-receptor autoantibodies, offering a promising alternative to conventional therapies. (AJMC)
- efgartigimod alfa and hyaluronidase-qvfc (VYVGART Hytrulo):
- Japan’s Ministry of Health, Labour and Welfare approved VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), offering a novel, effective, and convenient treatment option with a self-administered injection. (Globe Newswire, The Pharma Letter, Koin, Yahoo, The Pharma Data)
Other top Myasthenia Gravis (MG) & Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Discussions
- Cartesian Therapeutics announced updated Phase IIb data showing durable responses for its mRNA cell therapy Descartes-08 in generalized myasthenia gravis, and revealed plans to begin a pivotal Phase III trial, AURORA, in 2025. (MSN)
- A study using Medicare claims data from 2006 to 2019 found increasing trends in the prevalence and incidence of myasthenia gravis among the elderly US population, highlighting a growing disease burden. (Neurology Advisor)
Insmed
- Company Mentions:
- Insmed will present at the 43rd Annual J.P. Morgan Healthcare Conference. (Press Release)